ProQR Therapeutics Files 6-K, Announces Results
Ticker: PRQR · Form: 6-K · Filed: Mar 13, 2024 · CIK: 1612940
| Field | Detail |
|---|---|
| Company | Proqr Therapeutics N.V. (PRQR) |
| Form Type | 6-K |
| Filed Date | Mar 13, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, results-update
TL;DR
ProQR Therapeutics dropped a 6-K on March 13th with results – check it out.
AI Summary
ProQR Therapeutics N.V. filed a Form 6-K on March 13, 2024, to furnish a press release dated March 13, 2024. This press release announces the company's results, though the specific results are not detailed in the provided text.
Why It Matters
This filing indicates ProQR Therapeutics is providing an update on its performance or operations, which is important for investors to monitor the company's progress.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) to furnish a press release, not indicating any immediate material adverse events.
Key Players & Entities
- ProQR Therapeutics N.V. (company) — Filer of the Form 6-K
- March 13, 2024 (date) — Date of the Form 6-K filing and press release
FAQ
What specific results are announced in the press release furnished with this 6-K?
The provided text states that a press release dated March 13, 2024, announcing the Company's results is furnished as Exhibit 99.1, but the details of these results are not included in the excerpt.
What is the purpose of a Form 6-K filing?
A Form 6-K is a Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, typically used to furnish information that the company makes or is required to make public in its home country.
What is ProQR Therapeutics N.V.'s principal executive office address?
ProQR Therapeutics N.V.'s principal executive offices are located at Zernikedreef 9, 2333 CK Leiden, The Netherlands.
What is the Commission File Number for ProQR Therapeutics N.V.?
The Commission File Number for ProQR Therapeutics N.V. is 001-36622.
Does ProQR Therapeutics N.V. file annual reports under Form 20-F or Form 40-F?
ProQR Therapeutics N.V. indicates it files annual reports under cover of Form 20-F.
Filing Stats: 304 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2024-03-13 07:10:39
Filing Documents
- tm248631d1_6k.htm (6-K) — 12KB
- tm248631d1_ex99-1.htm (EX-99.1) — 35KB
- 0001104659-24-033735.txt ( ) — 48KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PROQR THERAPEUTICS N.V. Date: March 13, 2024 By: /s/ René Beukema René Beukema Chief Corporate Development Officer and General Counsel